Skip to main content
SpringerLink
Log in

Das ist die optimale Therapie bei übergewichtigen Typ-2-Diabetikern

Möglichst gewichtsneutral oder sogar gewichtssenkend

  • FORTBILDUNG
  • SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Besonders beim übergewichtigen Typ-2-Diabetiker muss bei der Wahl der antidiabetischen Therapie eine weitere Gewichtszunahme unbedingt vermieden, besser noch eine Gewichtsreduktion angestrebt werden. Dies führt nicht nur zu einer Besserung der Insulinempfindlichkeit, sondern auch zu einer höheren Patientenzufriedenheit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbildung 1

Literatur

  1. Colditz, G.A., et al., Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med, 1995. 122(7): p. 481–6.

    Article  PubMed  CAS  Google Scholar 

  2. Odegaard, J.I. and A. Chawla, Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science, 2013. 339(6116): p. 172–7.

    Article  PubMed  CAS  Google Scholar 

  3. Anderson, J.W., C.W. Kendall, and D.J. Jenkins, Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr, 2003. 22(5): p. 331–9.

    PubMed  Google Scholar 

  4. Knowler, W.C., et al., 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet, 2009. 374(9702): p. 1677–86.

    Article  PubMed  Google Scholar 

  5. Solomon, T.P., et al., A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr, 2010. 92(6): p. 1359–68.

    Article  PubMed  CAS  Google Scholar 

  6. Matthaei, S., et al., Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetologie und Stoffwechsel 2009 4: p. 32–64.

    Article  Google Scholar 

  7. Van Gaal, L.F. and C.E. De Block, Bariatric surgery to treat type 2 diabetes: what is the recent evidence? Curr Opin Endocrinol Diabetes Obes, 2012. 19(5): p. 352–8.

    PubMed  Google Scholar 

  8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p. 854–65.

    Google Scholar 

  9. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 2012. 35(4): p. 731–7.

    Google Scholar 

  10. Phung, O.J., et al., Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA, 2010. 303(14): p. 1410–8.

    Article  PubMed  CAS  Google Scholar 

  11. Nauck, M.A., Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med, 2011. 124(1 Suppl): p. S3–18.

    Article  PubMed  CAS  Google Scholar 

  12. Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring H.U., Jost, H.G., Kellerer, M., Kloos, C., Kunt, T., Nauck, M.A., Schernthaner, G., Siegel, E., Thienel, F., Behandlung des Diabetes mellitus Typ 2. Diabetologie und Stoffwechsel, 2012. 7: p. S 124–129.

    Article  Google Scholar 

  13. Kooy, A., et al., Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med, 2009. 169(6): p. 616–25.

    Article  PubMed  CAS  Google Scholar 

  14. Chao, E.C., A paradigm shift in diabetes therapy — dapagliflozin and other SGLT2 inhibitors. Discov Med, 2011. 11(58): p. 255–63.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II — Campus Großhadern, Klinikum der Universität München, Marchioninistraße 15, D-81377, München, Deutschland

    Jocelyn de Heer

  2. München, Deutschland

    Klaus Parhofer

Authors
  1. Jocelyn de Heer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klaus Parhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jocelyn de Heer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Heer, J., Parhofer, K. Das ist die optimale Therapie bei übergewichtigen Typ-2-Diabetikern. MMW - Fortschritte der Medizin 155, 43–47 (2013). https://doi.org/10.1007/s15006-013-0432-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-013-0432-0

Keywords - Antidiabetic drug therapy in overweight and obese adults with type 2 diabetes

Search

Navigation